skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

14 Total results for product and free and sample content found

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Pulmonary hypertension research wire

By Daniel Chancellor 01 Mar 2017

Pulmonary hypertension research wire

New clinical data and a deepening treatment algorithm will drive market growth

Topic Research wire

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Chronic Lymphocytic Leukemia

15 Feb 2017

While Rituxan-based therapies remain dominant in the first-line treatment setting for early- and late-stage chronic lymphocytic leukemia (CLL), the majority of patients with relapsed or refractory disease receive Imbruvica. 

Topic research-wire

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Praluent US sales block gives advantage to Amgen's Repatha in dyslipidemia

06 Jan 2017

On 5 January, Amgen secured a court ruling blocking Praluent (alirocumab; Sanofi/Regeneron) from being sold in the US. This ruling clears the way for Amgen’s Repatha (evolocumab) to potentially become the sole proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in the US market.

Topic research-wire

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Despite the failure of solanezumab’s EXPEDITION 3 trial, hope for the amyloid hypothesis lingers on

12 Dec 2016

At the 2016 Clinical Trials on Alzheimer’s Disease (CTAD) meeting, Eli Lilly provided a more detailed explanation for the failure of solanezumab in its pivotal EXPEDITION 3 study in mild Alzheimer’s disease.

Topic Research wire Alzheimers

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

AHA 2016: Type 2 diabetes treatment is shifting towards therapies with cardiovascular benefits

22 Nov 2016

Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans discussed how recent results from cardiovascular outcomes trials should affect current treatment and regulatory practices.

Topic research-wire

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

AHA 2016: Interim Data from ORION-1 Trial Encourage Further Development of Inclisiran

22 Nov 2016

Inclisiran offers patients a more convenient dosing schedule that may allow it to compete with marketed PCSK9 inhibitors when approved.

Topic research-wire

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

AHA 2016: EFFECT-HF supports use of iron deficiency as an independent therapeutic target in heart failure

22 Nov 2016

Topline results from the Phase III EFFECT-HF study of Injectafer (ferric carboxymaltose; Genesis Pharma/The Galenica Group/Zeria) and its impact on exercise capacity in chronic heart failure patients with iron deficiency were presented at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans.

Topic Research wire

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

AHA 2016: PIONEER-AF trial results will have minimal effect on Xarelto uptake

18 Nov 2016

Reduced doses of Xarelto were shown to lower the rate of bleeding in the PIONEER-AF trial. However, questions still remain as to how efficacious the smaller doses of Xarelto tested in the trial are at protecting against stroke.

Topic research-wire

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。